back to search abstracts online

Monday February 1,1999	Tuesday February 2, 1999	Wednesday February 3,1999	Thursday February 4,1999
Increased Plasma HIV RNA is Associated with Decreased Muscle Protein Synthesis Rate and Increased Plasma Myostatin Levels in AIDS-Wasting. Intestinal IL-15 and Interferong (IFNg) in Cryptoporidiosis Association Between Pneumocystis carinii Prophylaxis, P. carinii Molecular Genotype, and Clinical Outcomes Cerebrospinal Fluid Tumor Necrosis Factor (TNF)-[cancer] and Soluble TNF Receptors Levels in Cocaine Users and Patients with HIV-associated Dementia. Chemokine and Chemokine Receptor Gene Variants and Risk of AIDS-Related Non-Hodgkin's Lymphoma. HHV-8 Viremia in HIV-1 Infected Persons. Reconstitution of M. avium complex (MAC) immune responses after highly active antiretroviral therapy (HAART) ACTG 223: An Open, Prospective, Randomized, Study Comparing Efficacy and Safety of Clarithromycin (C) Plus Ethambutol (E), Rifabutin (R) or Both for Treatment (Rx) of MAC Disease in Pts. with AIDS. Lymphoproliferative Responses to CMV Predict CMV Retinitis Reactivation in Patients who Discontinued CMV Maintenance Therapy. Incidence and Risk Factors for Developing CMV Retinitis in HIV-Infected Patients Receiving Protease Inhibitor Therapy. Dramatic Rise in Plasma Viremia after CD8+ T-Cell Depletion in SIV-Infected Macaques. Evidence for importance of CD8+ T cells in controlling SIVmac infection using a CD8 cell depleting mAb in vivo in rhesus monkeys Emergence of Cytotoxic T Lymphocytes Coincides with Clearance of Virus during Primary SIV mac Infection in Rhesus Monkeys MHC Class I Immunogenetics and CTL Escape in a Family of MHC-Defined Macaques Infected with SIV. Containment of breakthrough HIV plasma viremia in the absence of antiretroviral drug therapy is associated with a broad and vigorous HIV specific cytotoxic T lymphocyte (CTL) response. Protection of Macaques Against Pathogenic SHIV-89.6PD by Passive Transfer of Neutralizing Antibodies. High RANTES Production from CD4+ Cells Correlates with Slower Progression to AIDS and with CCR5-D32 Heterozygocity CCR Variants, SDF-1 Polymorphism, and Disease Progression in 720 HIV-Infected Patients. Cytotoxic T Lymphocyte Responses to Human Herpesvirus 8 Lytic Proteins During Primary HHV-8 Infection. DURING THE TRANSMISSION OF HIV-1 FROM MATURE DENDRITIC CELLS TO T CELLS, THE FIRST ROUND OF VIRUS REPLICATION OCCURS IN DENDRITIC CELLS BY A CD40L DEPENDENT PATHWAY. Placentas Express Predominantly Type 2 Cytokines and CXCR4: Significant Downregulation of CXCR4 Occurs in Placentas from HIV-1 Transmitting Women Polymorphisms in the Regulatory Regions of the CCR5 Influence Perinatal Transmission of HIV. Genital Tract HIV Detection in Women: Association with Plasma Viral Load, CD4 Cell Count, Antiretroviral Therapy, Mode of Transmission Zidovudine Resistance After Vertical Transmission of HIV-1. Vertical Transmission of an HIV-1 Variant Resistant to Multiple Reverse Transcriptase and Protease Inhibitors. Zidovudine-lamivudine for Prevention of Mother to Child HIV-1 Transmission. Six Month Efficacy, Tolerance and Acceptability of a Short Course Regimen of Oral Zidovudine (Zdv) in Reducing Vertical Transmission of HIV in Breast-fed African Children: ANRS 049a. The CCR5D32 Genotype Slows Disease Progression In HIV Infected Children. Differential Time-to-First Decline in HIV-1 Plasma RNA in Children to Undetectable Levels (<400 vs <50 copies/mL): Virologic Implications of the Roche Standard (std) and Ultrasensitive (ultra) Assays. Abacavir /3TC/ZDV and 3TC/ZDV Reduce CSF HIV-1 RNA in Therapy-Experienced Children: Impact of Resistance Mutations. Demographic Correlates of HIV Incidence Among US Blood Donors. Natural History of HIV-1 Viremia After Seroconversion in the Multicenter AIDS Cohort Study Gender Specific Differences in Quantitative HIV-1 RNA levels Viral Load and CD4/CD8 Cell Count in Injecting Drug Users (IDUs) Newly Infected with HIV-1 Subtypes B' and E, Bangkok Seminal HIV-1 Viral Load Is Reduced by Antiretroviral Therapy and Is Correlated with Plasma HIV-1 Viral Load. Prevalence of HIV-1 drug resistance mutations in newly infected individuals remains stable over a 3 year period. Molecular Diversity of HIV-1 Group M Protease Gene Sequences Worldwide: Evidence for Naturally Occurring Drug-Resistant Mutations in Drug-Naive Individuals. Predominance of HIV-1 A/G Intersubtype Recombinants in Cameroon Significance Of Simultaneous Use Of Multiple HIV-1 Genomic Regions From Cell-Free And Cell-Associated Virus In Establishing Epidemiologic Linkage Between 4 Individuals Who Acquired HIV Via Surgical Procedure. Recent Epidemic of Primary HHV8 Infections Among Homosexual Men: Evidence for Oral-Genital Transmission A Potential Role for Matrix Metalloproteinases in the Development of HIV Dementia Mononuclear phagocytes secrete metalloproteinases that affect the neuropathogenesis of AIDS dementia Single Cell Calcium Flux Measurements in Response to Chemokines and HIV Envelopes in Microglia (MG) and MDM. Viral Load and Neurological Functioning. Evidence of Highly Neurotropic Strains of HIV-1 from Patients with AIDS Dementia Complex. Apoptosis induced by infection of primary brain cultures with diverse HIV-1 isolates: Evidence for a role of the envelope. Linkages Between Intracellular CXCR4 Signaling, Neuronal Apoptosis, and the Neuropathogenic Mechanisms for HIV-1-associated Dementia Chemokine receptor-mediated neuronal apoptosis in HIV-1-associated dementia: Signal transduction pathways and role of progeny virion and neural cell diversity Increased Monocyte Trafficking into Brain: a Prerequisite for HIV Dementia APJ, an Orphan 7TM Receptor, is Expressed in Astrocytes and Neurons. Early Events in the Neuropathogenesis of SIV Infection of Neonatal Rhesus Macaques Perivascular brain macrophages are a major target of SIV infection of the CNS at peak viremia and in SIVE. Inhibition of LTP by HIV-1-Infected Mononuclear Phagocyte Secretory Products: Implication for the Pathogenesis of HIV-1 Associated Dementia. Quantitation of HIV-1 RNA from Different Biological Compartments. CSF HIV-1 RNA In Asymptomatic Patients With Chronic HIV-1 Infection In Very Early Stage: Evidence Of A Local Production Of Virus. HIV-1 Compartmentalization and Discordant Virologic Failure in CSF and Plasma. HIV-1 RNA Levels In Brain Autopsy Samples and Patterns of AZT-Resistance. Phenotypic Evidence for Cellular Compartmentalization of AZT-resistant HIV-1 Compartmentalization of Subtype C HIV-1 Populations Between Blood and Semen As Assessed by V3-HTA Seminal Plasma HIV- 1 Burden During Acute and Early HIV-1 Infection. Mechanism of Shedding of HIV-1 in Semen. Evidence for Cell-free Virus in Cervicovaginal Lavage (CVL) Specimens as an Early Indicator of Productive Infection following Vaginal Exposure in a Pigtail Macaque Model for Human Retroviral (HIV-2) Infection. HIV-1 Compartmentalization: Fusion Co-Receptor Utilization by Viral Quasispecies from Lung versus Blood Detection of HIV-1 in Renal Epithelial Cells in Patients with HIV Associated Nephropathy. Reappearance of Founder Virus Sequences in HIV-1 Infected Individuals. A structured model of HIV populations predicts differences in the frequency of antiretroviral-resistant mutations seen between untreated patients. Are Multiple Compartments Necessary? The Within-Host Population Dynamics Of HIV And CD4+ T-Cells In Response To HAART. HLA-DR on T Cells Enhances HIV-1 Expression. The Human-Derived Co-Stimulatory Molecule CD28 is Incorporated into the Immunodeficiency Virus Type 1 Envelope and Increases its Infectivity. HIV Infectivity Depends upon Virion-Associated HLA-Class I Heavy Chains. Modulation of HIV-1 viral gene expression and replication by RhoA GTPase. Transcriptional Regulation of the Long Terminal Repeat of HIV-1 Subtype A through Evaluation of Expression of Cellular Genes Affecting Susceptibility to HIV-1 Infection in Normal Donors and Infected Patients. HIV-1-Infection of T Cells Increases their Responsiveness to NFAT- Activating Agents. HIV Induces a p38 Mitogen-Activated Protein Kinase-Independent ATF-2 Phosphorylation which Correlate with G2/M Phase Cell Cycle Arrest. Prolonged Expansion of T Cell Receptor CDR3-restricted CD4+ T Cells in the Chronically SIV-infected Macaques. Antiretroviral Therapy in Late Stage HIV Disease: Evidence for Immune Reconstitution. Analysis of the T cell receptor (TCR) Repertoire in HIV-infected Children Treated with Antiretroviral Therapy. A Rapid Decrease of sICAM-1 and sVCAM-1 May Explain the Redistribution of CD4+ T-cells in HIV Patients Early on HAART. Kinetics of Lymphocyte Proliferation, IL-2 and IL-4 Production in HIV-1 Infected Individuals Initiating HAART. Immunologic Reconstitution After 12 Months Of Antiretroviral Therapy In Very Early Stages Of Chronic HIV-1 Infection. Long-Term Recovery in CD4+ T Cell Function with Highly Efficient Antiretroviral Therapy. Immune Reconstitution of Advanced HIV Patients (Following HAART) Improved Immunologic Function Correlates with CD4 Rise after Highly Active Anti-Retroviral Therapy (HAART). Persistence of Follicular Hyperplasia in Previously Antiretroviral Naive HIV-Infected Patients After 6 Months on Aggressive Therapy. Immune Response to Antiretroviral Therapy in Gut Associated Lymphoid Tissue (GALT). Response to Immunization with Recall and Neoantigens after 48 Weeks of HAART. Immune Reconstitution, T cell Proliferation and Discordant Responses on HAART. Viral Fitness in Patients with Discordant CD4 and Plasma HIV RNA Evolution Following Protease Inhibitor Failure. Early contribution of CD4 and CD8 naive cells in immune reconstitution after HAART in antiretoviral naive patients. Assessment of Type-1 and Type-2 Cytokines in HIV-1 Infected Individuals: Impact of Highly Active Antiretroviral Therapy Differences in CXCR4 and CCR5 Expression in Early and Advanced Patients at Baseline and Changes and their Expression after HAART. Relationship Between Patient Age and CD4+ Lymphocyte Repletion Following Successful Virologic Responses to Highly Active Anti-Retroviral Therapy. Partial Immune Recovery of Phagocytic Function with HAART. Impact of Influenza Vaccination (IFV) on HIV plasma RNA and patterns of immune response (IR) in patients (pts) on HAART The Tap and Drain Model Holds True in HIV-1 Infected Lymph Nodes. The Impact of HAART. Changes in frequency of HIV-1 specific CTL precursors and circulating effectors after combination antiretroviral therapy in children. Alterations in T Cell Phenotype and Antigen-Specific Cytotoxicity in Patients Receiving Three Anti-retroviral Agents (ACTG Protocol 343) HIV-Specific CTL Dynamics in Response to HAART. Down regulation of CD8+ T cell expansions in HIV patients receiving highly active combination therapy. HIV-1 specific CD4+ T cell response is not restored after 28 months of HAART with Viral load (V.L) <50 copies. Prolonged Suppression of Plasma Viremia Results in Progressive Improvement in Immune Function Despite Possible Immunosuppressive Effects of Protease Inhibitors Immunological and virological evaluations of the effects of HAART compared to HAART plus an inactivated HIV immunogen after 32 weeks Administration of a Facilitated DNA Plasmid Vaccine Containing HIV-1 Env/Rev and Gag/Pol Genes to HIV-Infected Patients Also Receiving Highly Active Therapy. Indinavir, a HIV-1 protease inhibitor: Inhibition of lymphocyte activation and proliferation Prevention of HIV Associated T Cell Apoptosis by Inhibitors of HIV Protease. Development of In Vitro Resistance to Macrophage Tropic and T Cell Line Adapted Strains of HIV-1 Among HAART Treated HIV Positive Asymptomatic Volunteers Immune Control of HIV after Suspension of Therapy. Significantly Broadened Neutralization of Primary HIV Isolates and Partial Reconstitution of Cellular Immune Responses after HAART. Antibody Titers Prior to HAART Predict Treatment Outcome Evaluation of Subcutaneous Interleukin-2 Plus Antiretroviral Therapy vs. ARV alone in Patients with HIV-1 Infection and CD4+ Cell Count 350/mm3. Efficacy of a Four Arms Controlled Trial of Antivirals and Interleukin-2 in Drug-Experienced HIV-1+ Individuals with CD4 Counts 200-500 Cells/mm3. Antiviral and Immunological Effects of Interleukin-2 During Quadruple-drug Combination Therapy in Early HIV-1 Infection. A Randomized Controlled Multicenter Phase II Trial of Subcutaneous Interleukin-2 (scIL-2) Therapy in HIV-Infected Patients with CD4 Counts 200-500 cells/µL. HIV-1 induced in the setting of IL-2 therapy is transient and not derived from PBMC proviral reservoirs. Immunological Parameters Modified in HIV Disease by the Drug WF10 (a Phase II Pathogenesis Study). Adoptive T-Cell Transfer Combined with Highly Active Antiretroviral Therapy (HAART) in HIV-1 Discordant Twins. A PHASE I GENE THERAPY STUDY SHOWING SAFETY. FEASIBILITY AND SUSTAINED SURVIVAL OF ANTI-HIV-1 TRANSDUCED CD4+ T LYMPHOCYTES. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) ritonavir (RTV) combinations in healthy volunteers. Pharmacokinetics of an Indinavir/Ritonavir 800/100mg BID regimen. Co-administration of indinavir (IDV) 1200 mg with nelfinavir (NFV) 1250 mg in a twice daily regimen: Preliminary safety, PK activity. Pharmacokinetic (PK) Evaluation of Saquinavir Soft Gel Capsules (SQV)/Ritonavir (RTV) or SQV/Nelfinavir (NFV) in combination with Delavirdine (DLV) and/or Adefovir Dipivoxil (ADV) - - ACTG 359. Efavirenz (EFV) and Nelfinavir (NFV) Pharmacokinetics (PK) in HIV-Infected Children Participating in an Area Under the Curve (AUC) Controlled Trial. Pharmacokinetics of Efavirenz in Subjects with Chronic Liver Disease. Concentration-Controlled (CC) Antiretroviral Therapy with Zidovudine (ZDV), Lamivudine (3TC), and Indinavir (IDV): Pharmacokinetics (PK) and Safety. Therapeutic Drug Monitoring of Nelfinavir in HIV Patients with Liver Disease. Interaction of Methadone with Didanosine (ddI) and Stavudine (d4T) Nevirapine Induced Methadone Withdrawal: Implications for Antiretroviral Treatment of Opiate Dependent HIV Infected Patients. Ritonavir (RTV), Decreases Meperidine Exposure in HIV-Negative Subjects. Effect of the Reverse Transcriptase Inhibitor, Nevirapine, On the Steady-State Pharmacokinetics of Clarithromycin in HIV-Positive Patients. Effect of Demographic, Laboratory, and Clinical Covariates on the Pharmacokinetics of Amprenavir. Randomized Open-Label Study to Explore the Efficacy and Tolerability of Immediate versus Deferred Switching from ddI/d4T to AZT/3TC in a Thai HIV Infected Population Pretreated with ddI/d4T. Treatment Intensification with Ziagen in HIV Infected Patients with Previous 3TC/ZDV Antiretroviral Treatment-CNAB3009. Intensification of Stable Background Antiretroviral Therapy with Ziagen. The Preveon(r) Expanded Access Program: Safety of Adefovir Dipivoxil (ADV) in Antiretroviral Treatment Experienced Patients with Advanced HIV Disease. Phase I adult and pediatric studies of lodenosine (F-ddA) as monotherapy and combined with stavudine and nelfinavir. Substitution of NNRTI for Protease Inhibitor in Patients on Combination Therapy with Undetectable Plasma Viral Loads Durability of Response of Efavirenz (SUSTIVATM, EFV)-Containing Regimens: Report of the Post-Control Period Results of Studies with EFV. Efficacy of Efavirenz (SUSTIVATM) Containing Regimens in Patients with Baseline Plasma HIV-RNA Viral Loads Exceeding 100,000 copies/mL. Sustained Viral Suppression with Delavirdine and Indinavir Combination Therapies Intention-to-treat Analysis of a Placebo-Controlled Study Shows a Statistically Significant Reduction in the Incidence of Opportunistic Infections in the Delavirdine-Containing Arm. Amprenavir (141W94, APV USAN approved): Review of Overall Safety Profile. Liquid Ritonavir in clinical practice: Efficacy and Tolerability Treatment with Indinavir (IDV), Zidovudine (ZDV) and Lamivudine (3TC): Three-year follow-up. Quadruple Therapy with Saquinavir-Soft Gelatin Capsules (SQV-SGC) plus Nelfinavir (NFV) Versus Triple Therapy with Either SQV-SGC or NFV in Patients with Antiretroviral Experience or High Baseline Viral Load FORTOVASE BID Regimens in HIV-1 Infected Patients: Combination with 2 Nucleoside Analogs or with Nelfinavir plus 1 NA. A Randomized Open-Label Study to Explore the Antiretroviral Efficacy and Tolerability of d4T/ddI/SQV-SG versus combivir/SQV-SG in a Thai HIV infected population pretreated with AZT/ddC. 60-week virologic responses to a ritonavir/saquinavir containing regimen in patients who had previously failed nelfinavir A Phase II Study of Ritonavir-Nelfinavir Combination Therapy: 48-week Data* A Meta-Analysis of the Effects of HIV-1 RNA Methodology on Estimates of HIV-1 RNA Undetectability in Trials of HAART. Comparison of three Statistical Measures of HIV RNA Suppression in a Clinical Strategy Trial The Effect of HAART on Syncytium-inducing Variants of HIV. Dynamics of HIV-1 Proviral DNA Decay in Periphery of HIV-1 Infected Individuals Responsive to HAART. Treatment with d4T+ddI+Nelfinavir+Hydroxyurea for Early or Recent Primary HIV Infection. A pilot randomized comparative study of Stavudine (d4T) - Didanosine (ddI)+ Nevirapine (NVP) with or without Hydroxyurea (HU) in Primary HIV Infection (PHI). Surrogate Marker Responses To Multidrug Combinations Comprising Hydroxyurea, Efavirenz, Double Protease Inhibitors And Nucleoside Analogues In Protease Inhibitor Failures. Tailoring Drug Treatments with the Use of Hydroxyurea. Phase I/II Dosing Study of Once-Daily Hydroxyurea (HU) Alone vs Didanosine (ddI) Alone vs ddI + HU. The Prometheus Study: Double Protease Inhibitor (PI) Treatment Only is Unable to Suppress Detectable Viral Load in the CSF. More Than 2 Months of an Aggressive 4-Drug Antiretroviral Regimen is Required to Suppress CSF HIV Viral Burden in Previously Antiretroviral Naive Patients. Discordant HIV-1 RNA Decay in CSF versus Plasma Following Initiation of Antiretroviral Therapy: A Prospective Ultra-Intensive CSF Sampling Study. Estimation of Nevirapine Exposure within the Cerebrospinal Fluid Using CSF:Plasma Area Under the Curve Ratios. Levels of Serum and Cerebrospinal Fluid (CSF) Indinavir (IDV) and HIV RNA in HIV-Infected Individuals. Changes in CSF and Plasma HIV-1 RNA and in Neuropsychological Test Performance After Starting HAART. Cerebrospinal Fluid Changes during HIV-1 Infection: Normalization by Antiretroviral Therapy. The Changing Incidence of HIV-1-Related Neurological Diseases: 1990-1997. Increased Gelatinase B Activity in the CSF of Patients with HIV-Associated Neurological Diseases. Relationship between Kaposi's Sarcoma (KS), Kaposi's Sarcoma Associated Herpesvirus (KSHV) and AIDS Dementia Complex (ADC) AIDS-Related Focal Brain Lesions in the Era of HAART. The Fornix White Line is an Early Indicator of Cytomegalovirus Encephalitis. Immunoblot Profile as a Predictor of the Onset of Toxoplasma Encephalitis in HIV+ Patients: Data from a Primary Prophylaxis Trial. Evaluation of Thallium-201 SPECT combined with Toxoplasma Serology for Diagnosis of CNS Mass Lesions in AIDS. Experience of Cidofovir in IIIV-Associated Progressive Multifocal Leukoencephalopathy: Clinical and Virological Monitoring. Viral Dynamics in HIV-Infected Babies. Zidovudine Pharmacokinetics and Intracellular Pharmacology of Zidovudine in HIV-Infected Women and Newborn Infants. A Phase I Study of Hydroxyurea in HIV-Infected Children Receiving Didanosine (ddI) and/or Stavudine (d4T). Ritonavir (RTV) Pharmacokinetics and Dose Requirements in HIV Infected Children less than Two Years of Age. Development of an Indinavir Syrup to Treat HIV+ Children. Population Pharmacokinetics of Indinavir, Didanosine and Stavudine in Children. Pharmacokinetics of an Efavirenz Suspension in Children. Indinavir (IDV) in Combination with Stavudine (d4T) and Lamivudine (3TC) in HIV-Infected Children Long Term Outcome of Potent Antiretroviral Therapy in HIV-Infected Children. Nelfinavir Pharmacokinetics in Stable HIV Positive Children; The Effect of Weight and a Comparison of BID to TID Dosing. Safety and Effectiveness of Nelfinavir in Combination with 2 RTI in HIV-infected Children. Virologic and CD4 Response to Treatment with Nelfinavir in Therapy Experienced, Protease Inhibitor Naive HIV-Infected Children: 48 Week Follow-up. Pediatric Trial of Combination Therapy Including the Protease Inhibitor Amprenavir (APV) Dual HIV Protease Inhibitor (PI) Therapy of Children. Treatment of HIV Infected Children with Delavirdine Combined with Protease Inhibitors: Drug Levels, Safety, and Virologic Response. Preliminary Toxicity and Tolerability of 4-Drug Antiretroviral Therapy with NRTIs, Nevirapine, Nelfinavir & Ritonavir in ARV-Experienced Children with Advanced HIV Disease. Virologic Response to HAART and Modeling HIV Dynamics in Early Pediatric Infection. Hypercholesterolemia in Children Treated with HIV Protease Inhibitors. Gastrostomy Tube for Improvement of Adherence with HAART in Pediatric HIV Patients. The Effects of HAART on Immunophenotypic Markers in Perinatally HIV-1 Infected Children: Evidence for Reconstitution with Naive T Cells. Regeneration of CD4+45RA+ T lymphocytes in the presence of continued viral replication in HIV-infected children treated with 96 weeks of combination indinavir, 3TC and ZDV. CD4 Correlates of Opportunistic Infections in HIV-Infected Children during the Pre-HAART Era. Administration of Varicella Vaccine to HIV-Infected Children. Effects of Mycobacterium avium Infection on Simian Immunodeficiency Virus Replication in the Lymphoid Tissue of AIDS Macaques Killing of Mycobacterium avium by Neutrophils and Monocytes from AIDS Patients Treated with GM-CSF. Skin test reactivity to Mycobacterium avium sensitin among patients in ACTG 362 Predictors of Adherence to Azithromycin Prophylaxis for Prevention of Mycobacterium Avium Complex (MAC) Disease. Preclinical Development of Novel Anti-Mycobacterial Drugs: Activity In Vitro, Animal Model Efficacy, and Mechanism of Action. A Rapid Fall in Immune Activation During Antituberculosis Treatment of TB/HIV Coinfected Patients Has No Significant Impact on Plasma HIV-1 Load. Methylprednisolone in HIV + TB: Immunologic, Virologic and Pharmacodynamic Effects. Risk Factors for Developing Active Tuberculosis (TB) among HIV-Infected, PPD-Positive (+) Patients (Pts) Use of rifabutin (RBT) with protease inhibitors (PIs) for HIV-infected TB patients (pts). Effect of Cryopreservation on Cell-Mediated Immunity Assays Detection of Cytomegalovirus (CMV) pp67 Late Gene Transcripts by NASBA in Cerebrospinal Fluid:Correlation with CNS Disease in AIDS Patients. Analysis of Interstrain Variation in the Human Cytomegalovirus (CMV) DNA Polymerase (Pol) Sequence and its Effect on the Genotypic Diagnosis of Antiviral Drug Resistance. Prevalence of Asymptomatic CMV Retinitis (CMVR) in AIDS Patients. Recovery of Antibody Responses to Cytomegalovirus (CMV) Glycoprotein B (gB) Following Highly Active Antiretroviral Therapy (HAART) A 24 Month Follow-up of Cytomegalovirus Retinitis without Secondary Prophylaxis Following Highly Active Antiretroviral Therapy. RESTIMOP(ANRS 078): A Prospective Multicentre Study to Evaluate the Discontinuation of Maintenance Therapy for CMV Retinitis in HIV-Patients Receiving HAART. Decrease of CMV Replication in HIV Infected Patients after Treatment with Highly Active Antiretroviral Treatment. Risk of Cytomegalovirus Viremia and Disease in HIV-Infected Patients with Protease Inhibitor Treatment Failure. Quantitative Effects of Valaciclovir on the Replication of Cytomegalovirus in Patients with Advanced HIV Disease A Phase II Double Masked, Placebo-Controlled Evaluation of Standard Therapy vs Standard Therapy Combined with Human Monoclonal Anti-Cytomegalovirus Antibody (MSL-109) in the Therapy of AIDS Patients with Newly Diagnosed Cytomegalovirus (CMV) Retinitis in ACTG 266. Menstrual function and HIV serostatus. Incidence of HPV-Associated Vulvovaginal Lesions in HIV-Infected and Uninfected Women Cervical Neoplasia and the Persistence of HPV Infection in HIV+ Women Association of Retinol Deficiency with Cervical Squamous Intraepithelial Lesions (SIL) in the HIV-infected Women. Molecular Epidemiology of HPV Infection in the Genital Tract of HIV Seropositive Women. A PHASE THREE RANDOMIZED TRIAL OF TOPICAL VAGINAL 5-FLUOROURACIL MAINTENANCE THERAPY VERSUS OBSERVATION AFTER STANDARD TREATMENT FOR HIGH GRADE CERVICAL DYSPLASIA IN HIV-INFECTED WOMEN: ACTG 200 Cervicovaginal (CV) HIV DNA, RNA, and Markers of Inflammation in HIV+ Women Before and After Treatment for Vaginitis Syphilis Serologic Patterns Among Women With or At Risk for HIV. Utility of Cervigram in HIV infected Adolescents. HIV Testing Rates and Trends among U.S. Adults, 1994-1997. Urine Screening for Gonorrhea and Chlamydia in an HIV Primary Care Population. Identification of HIV Infection in High Risk Populations by Monthly Urine Screening. High-risk Sexual Behaviors Among HIV-infected Adolescents and Young Adults. High HIV-1 Seroprevalence Among Young Men Who Have Sex with Men (MSM) in New York City (NYC) High HIV seroprevalence in men diagnosed with gonorrhea during a period of declining HIV seroprevalence and gonorrhea incidence, New York City (NYC) Dept. of Health (DOH) Sexually Transmitted Disease (STD) Clinics, 1990-1997. Differences in HIV incidence by risk exposure and gender in patients accepting confidential HIV testing at two New York City (NYC) Dept. of Health (DOH) Sexually Transmitted Disease (STD) Clinics, 1994-1998. Trends in HIV Seroprevalence Among Illicit Drug Users Entering Drug Treatment Centers in NYC, 1991 - 1997: A Birth Cohort Analysis. Community Incidence and Prevalence of HIV and Hepatitis in Incarcerated Women in Rhode Island. A High-Incidence Homosexual Male Cohort for Vaccine Trials in Brazil. Estimation of HIV-1 Incidence in an Anonymous Testing Center in Brazil Using a dual EIA Testing Strategy. The Changing Epidemiology of HIV Infection in Ireland. A Continuous Multicenter Quality Assurance Monitoring Program for HIV-1 RNA Measurements in Europe and Asia. Evaluation of a Nucleic Acid Sequence Based Amplification (NASBA) Assay for Screening of CCR5 Genotype Utilizing Peripheral Blood Mononuclear Cells (PBMCs) and Whole Blood of HIV-1 Infected Individuals. DIAGNOSIS OF HIV, HEPATITIS B AND HEPATITIS C IN A HIGH RISK POPULATION USING ORAL FLUID. Improving the Standards of HHV-8 Serological Testing: Use of Well-Characterized Clinical Samples and a Sensitive IFA to Establish True Positive and True Negative Controls for the Calibration of a New ELISA. Dual EIA Test Strategy for Enrolling Persons with Recent HIV Infection into a Primary HIV Treatment Trial.

© 6th Conference on Retroviruses and Opportunistic Infections,
Foundation for Retrovirology and Human Health

This site designed and maintained by:
© Medical Consumer Media. All Rights Reserved.
For inquiries, contact: retroinfo@medcm.com

The broadcasts of selected invited sessions from the 6th Conference on Retroviruses and Opportunistic Infections are for individual, non-commercial use only. No portion of this site (including speakers' audiotrack, slides, and abstracts) may be copied, reproduced, or rebroadcast without the express advanced written permission of the speaker(s) and the Conference Secretariat.